Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) closed the day trading at $8.64 up 1.05% from the previous closing price of $8.55. In other words, the price has increased by $1.05 from its previous closing price. On the day, 1.85 million shares were traded. DAWN stock price reached its highest trading level at $8.74 during the session, while it also had its lowest trading level at $8.43.
Ratios:
For a better understanding of DAWN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.55 and its Current Ratio is at 8.68. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In the most recent recommendation for this company, Piper Sandler on August 19, 2025, initiated with a Overweight rating and assigned the stock a target price of $25.
On October 09, 2024, Needham reiterated its Buy rating and also lowered its target price recommendation from $32 to $33.
BofA Securities Upgraded its Underperform to Buy on August 01, 2024, whereas the target price for the stock was revised from $11 to $24.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 17 ’25 when Dubow Adam sold 4,319 shares for $8.91 per share. The transaction valued at 38,503 led to the insider holds 62,626 shares of the business.
York Charles N II sold 4,062 shares of DAWN for $36,212 on Nov 17 ’25. The COO and CFO now owns 294,715 shares after completing the transaction at $8.91 per share. On Nov 17 ’25, another insider, Merendino Lauren, who serves as the Chief Commercial Officer of the company, sold 3,726 shares for $8.91 each. As a result, the insider received 33,216 and left with 50,809 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DAWN now has a Market Capitalization of 887116416 and an Enterprise Value of 438429344. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.64 while its Price-to-Book (P/B) ratio in mrq is 1.97. Its current Enterprise Value per Revenue stands at 3.28 whereas that against EBITDA is -2.7.
Stock Price History:
The Beta on a monthly basis for DAWN is -1.27, which has changed by -0.29918033 over the last 52 weeks, in comparison to a change of 0.16623151 over the same period for the S&P500. Over the past 52 weeks, DAWN has reached a high of $13.53, while it has fallen to a 52-week low of $5.64. The 50-Day Moving Average of the stock is -0.75%, while the 200-Day Moving Average is calculated to be 16.39%.
Shares Statistics:
Over the past 3-months, DAWN traded about 2.44M shares per day on average, while over the past 10 days, DAWN traded about 1643210 shares per day. A total of 102.68M shares are outstanding, with a floating share count of 73.65M. Insiders hold about 28.27% of the company’s shares, while institutions hold 72.18% stake in the company. Shares short for DAWN as of 1765756800 were 9374807 with a Short Ratio of 3.85, compared to 1763078400 on 8969860. Therefore, it implies a Short% of Shares Outstanding of 9374807 and a Short% of Float of 13.5.
Earnings Estimates
. The current market rating for Day One Biopharmaceuticals Inc (DAWN) reflects the collective analysis of 7.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.19, with high estimates of -$0.1 and low estimates of -$0.25.
Analysts are recommending an EPS of between -$0.62 and -$1.2 for the fiscal current year, implying an average EPS of -$0.98. EPS for the following year is -$0.63, with 8.0 analysts recommending between -$0.07 and -$1.6.
Revenue Estimates
9 analysts predict $44.1M in revenue. The current quarter. It ranges from a high estimate of $46.7M to a low estimate of $37.54M. As of. The current estimate, Day One Biopharmaceuticals Inc’s year-ago sales were $29.2MFor the next quarter, 9 analysts are estimating revenue of $50.86M. There is a high estimate of $54.1M for the next quarter, whereas the lowest estimate is $47.8M.
A total of 10 analysts have provided revenue estimates for DAWN’s current fiscal year. The highest revenue estimate was $151.2M, while the lowest revenue estimate was $142M, resulting in an average revenue estimate of $148.51M. In the same quarter a year ago, actual revenue was $131.16MBased on 10 analysts’ estimates, the company’s revenue will be $222.81M in the next fiscal year. The high estimate is $295M and the low estimate is $165.99M.
